Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

Galunisertib, a Transforming growth factor-βRI (TGF-βRI) kinase inhibitor, blocks TGF-β-mediated tumor growth in glioblastoma. In a three-arm study of galunisertib (300 mg/day) monotherapy (intermittent dosing; each cycle =14 days on/14 days off), lomustine monotherapy, and galunisertib plus lomusti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Mol Sci
Main Authors: Capper, David, von Deimling, Andreas, Brandes, Alba A., Carpentier, Antoine F., Kesari, Santosh, Sepulveda-Sanchez, Juan M., Wheeler, Helen R., Chinot, Olivier, Cher, Lawrence, Steinbach, Joachim P., Specenier, Pol, Rodon, Jordi, Cleverly, Ann, Smith, Claire, Gueorguieva, Ivelina, Miles, Colin, Guba, Susan C., Desaiah, Durisala, Estrem, Shawn T., Lahn, Michael M., Wick, Wolfgang
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5454908/
https://ncbi.nlm.nih.gov/pubmed/28481241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18050995
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados